Alzheimer's Disease treatment: a novel approach

  • Alzheimer's disease (AD) is particularly devastating since there is no cure, no way to prevent it and no proven way to slow its progression.

  • Management of AD represents a huge unmet need; thus, discovery and development of more effective therapies are critical for worldwide public health and health-care systems.

  • Novel strategy for symptomatic & disease-modifying treatment of Alzheimer's disease hitting two targets, epigenetic (HDAC) and non-epigenetic (PDES). Proof of Concept using reference compounds (vorinostat and tadalafil).

    • In vitro, using primary neuronal cultures: synergistic effect on epigenetic mark (histone acetylation).

    • Ex vivo, using hippocampal slices from AD mice (APP/PS1): synergistic effect in long term potentiation (LTP).

    • In vivo,  using AD mice (Tg2576): behavior studies and AD pathological marks.

  • Novel proprietary compounds, first‐in class dual inhibitors (HDAC and PDE5) show safety and efficacy in reversing AD phenotype using transgenic mice (APP/PS1, Tg2576).

> Download more information

Novel target in CNS: GluN3A in HD and drug abuse

  • There is an unmet need for effective therapeutic strategies in Huntington's disease (HD) and drug abuse

  • GluN3A is a novel target that regulates synapse plasticity and neuronal connectivity.

    • Its expression is reactivated in CNS pathologies including HD, cocaine and alcohol abuse.

    • Proof of Concept: Knock-Out mice in HD and shRNA in drug abuse.

    • Safety:  lacking in healthy adult brain.

Contact us:

Center for Applied Medical Research (CIMA)
Avenida Pío XII, 55
31008 Pamplona

+34 948 194700